BETHEL, Conn., Dec. 2 /PRNewswire-FirstCall/ -- Aduromed Industries, Inc. (OTC Bulletin Board: ADRM), a leading provider of medical waste treatment systems, today announced that it successfully filed a U.S. patent on November 24, 2008 to protect the Company's proprietary technology for its new standard, containerized MedClean Systems that provide a turnkey solution for onsite regulated medical waste sterilization and volume reduction.

The patent application, entitled "Containerized Medical Waste Treatment System and Related Method," focuses on the design and configuration of Aduromed's new standard, containerized MedClean Systems.

"The Aduromed team has invested significant time and effort into evolving its operating model to meet the business and regulatory demands of the health care institutions it targets," commented Scott Grisanti, President and Chief Executive Officer of Aduromed. "The resultant solutions have the potential to produce a sustainable competitive advantage, and we have taken significant steps to protect this intellectual property through this patent filing. The patent pre-stages market introduction of the MedClean series of containerized systems that are designed to make it easier for health care institutions to implement onsite processing solutions for regulated medical waste that reduce costs, mitigate risk, and enhance Green profiles."

The patent application also covers the specific protocol employed to accomplish sterilization in the company's autoclave subsystem. The protocol implements a sequence of differential heating and vacuum cycles designed to optimize efficacy and balance cycle time.

"The treatment protocol included in the patent is the result of research conducted with customers and industry experts that has yielded the most extensive body of work in the industry," added Mr. Grisanti. "This tested and validated protocol is a key component of our proprietary software and hardware platform, enabling MedClean solutions to meet and exceed the most demanding efficacy standards throughout all 50 states while providing the throughput required to economically address the highest volume generators of regulated medical waste. Our third-party validated efficacy results, combined with first in industry MedClean container configurations, are expected to accelerate adoption of Aduromed's solutions."

About Aduromed

Aduromed Industries, Inc., through its wholly-owned subsidiary, Aduromed Corporation, is a provider of innovative technology and services for the onsite treatment and disposal of regulated medical waste. Aduromed's flagship MedClean(R) Series systems are fully integrated, turnkey technology solutions that enable hospitals and other healthcare providers to safely, efficiently and cost-effectively convert bio-hazardous regulated medical waste into sterile, unrecognizable material suitable for disposal as municipal solid waste.

Aduromed was founded in 1997 with corporate headquarters, research and development, and distribution facilities located in Bethel, Connecticut. Further information on Aduromed can be found at http://www.aduromed.com and in filings with the Securities and Exchange Commission found at http://www.sec.gov.

Statements about our future expectations are "forward-looking statements" within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance. When used herein, the words "may," "will," "should," "anticipate," "believe," "appear," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements. These statements involve risks and uncertainties inherent in our business, including those set forth in our most recent Annual Report on Form 10-K for the year ended December 31, 2007, filed with the SEC on March 31, 2008, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.

SOURCE Aduromed Industries, Inc.